Akero Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.03.24	Akero Therapeutics Commences Public Offering Of $300 Mln Of Shares (RTTNews)
04.03.24	Akero Therapeutics Releases Preliminary Topline Week 96 Results From Efruxifermin Phase 2b Study (RTTNews)
10.10.23	Akero Therapeutics Stock Plunges On 36-Week Analysis Of Phase 2b SYMMETRY Study (RTTNews)
10.10.23	Pre-market Movers: AKRO, MOB, VTYX, PGTI, PRZO… (RTTNews)
08.12.22	Akero Therapeutics Announces Breakthrough Therapy Designation For Efruxifermin (RTTNews)
14.10.22	Did These 6 Biotech Stocks Catch Your Eye? (RTTNews)
07.10.22	These Biotech Stocks Hit New 52-week High, Were They In Your Portfolio? (RTTNews)
14.09.22	In der HARMONY-Studie der Phase 2b von Akero Therapeutics wurde in der 50-mg- und der 28-mg-EFX-Dosisgruppe nach 24 Wochen statistische Signifikanz bei primären und sekundären histologischen Endpunkte (GlobeNewswire)
13.09.22	Pre-market Movers: AKRO, ETNB, CMRA, RENT, CRDF… (RTTNews)
13.09.22	Akero Therapeutics: 24-week Phase 2b Study With Efruxifermin Meets Primary Endpoint (RTTNews)
13.09.22	In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks (GlobeNewswire)
01.09.22	Akero Therapeutics To Report NASH Trial Data In September (RTTNews)
01.07.20	AKRO Soars After-hrs, ATHE On Watch, INO Reports COVID-19 Vaccine Trial Data, ZYNE Down But Not Out (RTTNews)
30.06.20	After Market Hours: Akero Therapeutics, FedEx, Carver Bancorp Jump; Chiasma, Steelcase Slip (RTTNews)
30.06.20	FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA? (RTTNews)
31.03.20	Well-Balanced: Akero Therapeutics (AKRO) Reports Encouraging NASH Trial Data (RTTNews)
31.03.20	AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)
24.03.20	9 Pharma/Biotech Stocks To Watch This Week, Here's Why... (RTTNews)
09.03.20	Will Akero's (AKRO) NASH Data Delight Investors? (RTTNews)
17.12.19	AXSM Again Proves It Is Awesome, MIRM Leaps To $22, WVE Doesn't Go The Distance (RTTNews)
12.12.19	Healthcare IPOs That Delivered Solid Returns In 2019 (RTTNews)
10.09.19	5 Top Losers In Healthcare Sector (NTRP, AKRO, SAVA...) (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Akero Therapeutics Inc Registered Shs Accred Inv

Aktien Top/Flop

Meistgelesene Nachrichten